Trial Profile
A retrospective study of Prolactin and associated clinical outcomes in non-small cell lung cancers (NSCLC) patients treated with Nivolumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress